CA2607151C - Hiv integrase inhibitors - Google Patents

Hiv integrase inhibitors Download PDF

Info

Publication number
CA2607151C
CA2607151C CA2607151A CA2607151A CA2607151C CA 2607151 C CA2607151 C CA 2607151C CA 2607151 A CA2607151 A CA 2607151A CA 2607151 A CA2607151 A CA 2607151A CA 2607151 C CA2607151 C CA 2607151C
Authority
CA
Canada
Prior art keywords
alkyl
fluorobenzyl
chloro
naphthyridine
alkylene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2607151A
Other languages
English (en)
French (fr)
Other versions
CA2607151A1 (en
Inventor
Joseph P. Vacca
John S. Wai
Linda S. Payne
Richard C. A. Isaacs
Wei Han
Melissa Egbertson
Richard Pracitto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme LLC
Publication of CA2607151A1 publication Critical patent/CA2607151A1/en
Application granted granted Critical
Publication of CA2607151C publication Critical patent/CA2607151C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2607151A 2005-05-10 2006-05-05 Hiv integrase inhibitors Expired - Fee Related CA2607151C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67943105P 2005-05-10 2005-05-10
US60/679,431 2005-05-10
PCT/US2006/017369 WO2006121831A2 (en) 2005-05-10 2006-05-05 Hiv integrase inhibitors

Publications (2)

Publication Number Publication Date
CA2607151A1 CA2607151A1 (en) 2006-11-16
CA2607151C true CA2607151C (en) 2012-06-19

Family

ID=37397115

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2607151A Expired - Fee Related CA2607151C (en) 2005-05-10 2006-05-05 Hiv integrase inhibitors

Country Status (7)

Country Link
US (4) US7741315B2 (enExample)
EP (1) EP1881825B1 (enExample)
JP (1) JP4982482B2 (enExample)
AU (1) AU2006244424B2 (enExample)
CA (1) CA2607151C (enExample)
TW (1) TW200819126A (enExample)
WO (1) WO2006121831A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007528396A (ja) 2004-03-09 2007-10-11 メルク　エンド　カムパニー　インコーポレーテッド Ｈｉｖインテグラーゼ阻害薬
EP1725556A1 (en) 2004-03-09 2006-11-29 Merck & Co., Inc. Hiv integrase inhibitors
JP2007528394A (ja) * 2004-03-09 2007-10-11 メルク　エンド　カムパニー　インコーポレーテッド Ｈｉｖインテグラーゼ阻害薬
US7897592B2 (en) 2005-11-15 2011-03-01 Bristol-Myers Squibb Company HIV integrase inhibitors
US7902182B2 (en) 2005-11-16 2011-03-08 Bristol-Myers Squibb Company HIV integrase inhibitors
US8039458B2 (en) 2005-11-17 2011-10-18 Bristol-Myers Squibb Company HIV integrase inhibitors
CA2645551C (en) 2006-03-16 2016-06-28 Renovis, Inc. Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
US7897593B2 (en) 2006-05-30 2011-03-01 Bristol-Myers Squibb Company HIV integrase inhibitors
US7893055B2 (en) 2006-06-28 2011-02-22 Bristol-Myers Squibb Company HIV integrase inhibitors
AU2007313293A1 (en) * 2006-10-18 2008-04-24 Merck & Co., Inc. HIV integrase inhibitors
US7763630B2 (en) 2007-06-06 2010-07-27 Bristol-Myers Squibb Company HIV integrase inhibitors
US8129398B2 (en) 2008-03-19 2012-03-06 Bristol-Myers Squibb Company HIV integrase inhibitors
US8143244B2 (en) 2009-02-26 2012-03-27 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US8383639B2 (en) 2009-10-15 2013-02-26 Bristol-Myers Squibb Company HIV integrase inhibitors
US8283366B2 (en) 2010-01-22 2012-10-09 Ambrilia Biopharma, Inc. Derivatives of pyridoxine for inhibiting HIV integrase
CA2814703A1 (en) * 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. Hiv integrase inhibitors
WO2012131539A1 (en) 2011-03-31 2012-10-04 Pfizer Inc. Novel bicyclic pyridinones
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
WO2014172188A2 (en) 2013-04-16 2014-10-23 Merck Sharp & Dohme Corp. 4-pyridone derivative compounds and uses thereof as hiv integrase inhibitors
TN2017000342A1 (en) 2015-02-03 2019-01-16 Pfizer Novel cyclopropabenzofuranyl pyridopyrazinediones

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2329134A1 (en) * 1998-06-03 1999-12-09 David L. Clark Hiv integrase inhibitors
US6380249B1 (en) * 1998-06-03 2002-04-30 Merck & Co., Inc. HIV integrase inhibitors
US6306891B1 (en) * 1998-06-03 2001-10-23 Merck & Co., Inc. HIV integrase inhibitors
US6262055B1 (en) * 1998-06-03 2001-07-17 Merck & Co., Inc. HIV integrase inhibitors
JP2003503386A (ja) * 1999-06-25 2003-01-28 メルク エンド カムパニー インコーポレーテッド １−（芳香族またはヘテロ芳香族置換）−３−（ヘテロ芳香族置換）−１，３−プロパンジオン類およびそれの使用
DE60124577T2 (de) * 2000-10-12 2007-09-27 Merck & Co., Inc. Aza- und polyaza-naphthalenylcarbonsäureamide als hiv-integrase-hemmer
WO2002036734A2 (en) * 2000-10-12 2002-05-10 Merck & Co., Inc. Aza-and polyaza-naphthalenyl ketones useful as hiv integrase inhibitors
AU1532802A (en) * 2000-10-12 2002-04-22 Merck & Co Inc Aza- and polyaza-naphthalenyl-carboxamides useful as hiv integrase inhibitors
ATE430745T1 (de) * 2000-10-12 2009-05-15 Merck & Co Inc Aza- und polyaza naphthalenyl karboxamide als inhibitoren der hiv-integrase
DK3042894T1 (da) * 2001-08-10 2016-11-07 Shionogi & Co Antiviralt middel
SI1441734T1 (sl) * 2001-10-26 2007-08-31 Angeletti P Ist Richerche Bio Dihidropirimidin karboksamidni inhibitorji HIV-integraze
DE60209381T2 (de) * 2001-10-26 2006-10-05 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. N-substituierte hydroxypyrimidinoncarboxamid-hemmer der hiv-integrase
ES2291642T3 (es) * 2002-01-17 2008-03-01 MERCK & CO., INC. Hidroxinaftiridinoncarboxamidas utiles como inhibidores de la integrasa de vih.
AU2003248872A1 (en) * 2002-07-09 2004-01-23 Bristol-Myers Squibb Company Hiv integrase inhibitors
PA8586801A1 (es) * 2002-10-31 2005-02-04 Pfizer Inhibidores de hiv-integrasa, composiciones farmaceuticas y metodos para su uso
TW200510425A (en) * 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
EP1725556A1 (en) * 2004-03-09 2006-11-29 Merck & Co., Inc. Hiv integrase inhibitors
JP2007528396A (ja) 2004-03-09 2007-10-11 メルク　エンド　カムパニー　インコーポレーテッド Ｈｉｖインテグラーゼ阻害薬
CA2557926A1 (en) * 2004-03-09 2005-09-22 Monica Donghi Hiv integrase inhibitors
PT1874117E (pt) 2005-04-28 2013-10-17 Shionogi & Co Derivado policíclico de carbamoílpiridona possuindo actividade inibidora de hiv-integrasse

Also Published As

Publication number Publication date
CA2607151A1 (en) 2006-11-16
AU2006244424B2 (en) 2011-09-22
US20110275621A1 (en) 2011-11-10
WO2006121831A2 (en) 2006-11-16
US20100204201A1 (en) 2010-08-12
EP1881825B1 (en) 2013-07-24
JP4982482B2 (ja) 2012-07-25
EP1881825A4 (en) 2011-11-30
US20090054399A1 (en) 2009-02-26
US7741315B2 (en) 2010-06-22
TW200819126A (en) 2008-05-01
US20130178468A1 (en) 2013-07-11
WO2006121831A3 (en) 2007-10-25
AU2006244424A1 (en) 2006-11-16
JP2008540529A (ja) 2008-11-20
EP1881825A2 (en) 2008-01-30
US8293731B2 (en) 2012-10-23
US7968564B2 (en) 2011-06-28

Similar Documents

Publication Publication Date Title
US8293731B2 (en) HIV integrase inhibitors
JP6177456B2 (ja) 二環式縮合ヘテロアリールまたはアリール化合物およびｉｒａｋ４阻害剤としてのそれらの使用
US20100216834A1 (en) Hiv integrase inhibitors
AU2007275816A1 (en) 1-hydroxy naphthyridine compounds as anti-HIV agents
WO2017001307A1 (en) Novel substituted aminothiazolopyrimidinedione for the treatment and prophylaxis of virus infection
EP1725554A1 (en) Hiv integrase inhibitors
AU2005220767A1 (en) HIV integrase inhibitors
KR20180005673A (ko) 인간 면역결핍 바이러스 복제 억제제
AU2014267951A1 (en) Fused Tricyclic Heterocyclic compounds as HIV integrase inhibitors
KR20070026414A (ko) Ｈｉｖ 인테그라제 억제제
JP2026508745A (ja) アミド又はウレア系化合物
JP2022554385A (ja) Ｗｄｒ５阻害剤及び調節剤
EP2470014A1 (en) Hiv integrase inhibitors
WO2009154870A1 (en) Hiv integrase inhibitors
JP5094725B2 (ja) Ｈｉｖインテグラーゼ阻害剤
FR2850654A1 (fr) Nouveaux derives d'azepines tricycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA2542047A1 (en) Hydroxy pyridopyrrolopyrazine dione compounds useful as hiv integrase inhibitors
MXPA06010252A (en) Hiv integrase inhibitors

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20150505